Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Eye Melanoma Market Size And Revenue Forecast Through 2030

The market for eye melanoma has experienced robust expansion recently, with projections indicating continued growth from $9.86 billion in 2025 to $10.69 billion in 2026, reflecting a compound annual growth rate of 8.4%. This historical growth trajectory can be attributed to several key factors, including breakthroughs in ocular imaging, heightened public awareness of cancer, the proliferation of oncology treatment centers, enhanced diagnostic tools, and a general improvement in patient survival rates.

The market for eye melanoma is projected for significant expansion over the upcoming years, reaching an estimated $15.17 billion by 2030, propelled by a compound annual growth rate (CAGR) of 9.1%. This forecasted expansion is anticipated to be fueled by advancements in innovative immunotherapies, a growing embrace of precision oncology strategies, increased utilization of genetic testing services, augmented investments in research concerning rare cancers, and enhancements in early detection screening initiatives. Key developments anticipated during this forecast period involve a heightened emphasis on identifying cancer at its earliest stages, the escalating adoption of targeted and immune-based therapeutic approaches, more widespread application of sophisticated ocular imaging technologies, the proliferation of specialized cancer treatment facilities, and a surge in clinical investigations dedicated to rare forms of eye cancer.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13109&type=smp

Eye Melanoma Market Growth Factors: Which Forces Are Supporting Market Expansion?

The expanding incidence of eye cancer is anticipated to be a significant catalyst for the trajectory of the eye melanoma market in the future. Eye cancer is characterized by the aberrant proliferation and unregulated division of cells within the various components of the eye. A greater understanding and successful handling of instances detected at their onset are fostering a heightened demand for tailored treatments and medical interventions, spurred by enhancements in diagnostic capabilities, amplified public consciousness, and progress in therapeutic approaches. To illustrate, in the year 2025, the American Cancer Society, a charitable organization based in the United States, reported an estimated 3,140 new diagnoses of cancers affecting the eye and orbit, with melanomas being the predominant type, encompassing 1,620 cases in males and 1,520 cases in females. Additionally, fatalities attributed to these cancers numbered around 490, consisting of 270 males and 220 females. Consequently, the rising occurrence of eye cancer is poised to stimulate expansion within the eye melanoma market.

Eye Melanoma Market Segment Performance And Strategic Opportunities

The eye melanoma market covered in this report is segmented –

1) By Site: Uvea, Sclera, Retina

2) By Diagnosis: Imaging, Biopsy, Eye Exam

3) By Treatment: Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Other Treatment

4) By End User: Hospitals And Clinics, Academic Institutes

Subsegments:

1) By Uvea: Choroid Melanoma, Ciliary Body Melanoma, Iris Melanoma

2) By Sclera: Episcleral Melanoma, Scleral Surface Melanoma, Conjunctival Melanoma

3) By Retina: Macular Melanoma, Peripheral Retinal Melanoma, Optic Disc Melanoma

Eye Melanoma Market Industry Trends: What Changes Are Reshaping Demand?

The eye melanoma sector is characterized by significant players concentrating on innovative solutions like protein-kinase C (PKC) inhibitors, driven by an increasing need for treatments that preserve the eye and are effective systemically. These PKC inhibitors function as targeted small molecules that inhibit specific PKC enzymes contributing to tumor proliferation, thus presenting a non-surgical option compared to conventional methods like plaque brachytherapy or enucleation. To illustrate, IDEAYA Biosciences, an American precision oncology firm, introduced darovasertib in March 2025, a novel PKC inhibitor designed for uveal melanoma. This treatment aims at PKC isoforms associated with cancer cell multiplication, and Phase 2 studies indicated an approximate 82% tumor reduction alongside a 61% eye preservation rate. Darovasertib provides a systemic, eye-conserving alternative for primary uveal melanoma, applicable to patients who are candidates for either enucleation or plaque brachytherapy.

Eye Melanoma Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the eye melanoma market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc, AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Amgen Inc., Castle Biosciences Inc., IDEAYA Biosciences Inc., Delcath Systems Inc., Immunocore Holdings plc, Aura Biosciences Inc., TriSalus Life Sciences Inc., Replimune Group Inc., Linnaeus Therapeutics, iOnctura, LES LABORATOIRES SERVIER, Immatics NV

Access The Complete Eye Melanoma Market Report:

https://www.thebusinessresearchcompany.com/report/eye-melanoma-global-market-report

Eye Melanoma Market Global Footprint: Which Region Holds Market Leadership?

North Americawas the largest region in the eye melanoma market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the eye melanoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model